bluuebunny/crossref_metadata_2025_split huggingface dataset:
Total Skin Electron Beam Irradiation for Generalized Cutaneous Lymphoma
Authors: Prescott D. M. , Gordon J. 
Published: September 2010

Introduction:  Generalized cutaneous T‐cell lymphoma (CTCL) in canines has many similarities to CTCL in humans. In humans, early stage mycosis fungoides (MF) patients that do not have lymph node or any systemic involvement can do very well with total skin electron beam irradiation (TSE). In fact, if these early stage patients were treated with 30–35 Gy, the median overall survival was not reached at 15 years. Only one dog with CTCL has been treated with total skin irradiation using orthovoltage irradiation. The patient died the night of the 2nd fraction of RT. Now that more veterinary RT facilities have linear accelerators with electron beam capabilities, it is possible canines with CTCL can be treated with TSE. This paper describes an adaptation of the Modern TSE technique used in human MF patients and its application in canine patients with MF/CTCL.Methods:  The modified Modern TSE technique and its application for canine MF/CTCL patients involves 20 treatments given M‐F over 4 weeks. The entire skin surface is treated from multiple directions.Results:  Four canine patients with CTCL have been treated with this TSE technique. All patients responded to the treatment initially with the first patient having tumor control for >20 months. One patient has failed the therapy at this date.Conclusions:  The TSE technique adapted for use in canines with CTCL was well tolerated with no significant toxicity noted. Development of a collaborative study with other veterinary RT centers having electron beam capabilities is being evaluated through VRTOG.
Feline Sinonasal Neoplasia: CT Staging and Prognosis with Mega Voltage Radiation Therapy
Authors: De Lorimier L. P. , Fan T. M. , Haney S. , Grimm J. B. , Charney S. C. , Clifford C. A. 
Published: September 2010

Introduction:  Megavoltage radiation is considered standard therapy for feline sinonasal neoplasia, but a paucity of published reports and the lack of a staging system based on advanced sectional imaging render accurate prognostication difficult. The aims of this retrospective study on feline sinonasal neoplasia were to adapt or develop a staging system based on advanced imaging, and to further define the prognosis with megavoltage radiation therapy.Methods:  Medical records were reviewed, and CT images were evaluated by a single radiologist (JBG) and staged using a modified system previously reported for dogs. Further follow‐up information was obtained by telephone interviews with the referring veterinarians or owners.Results:  Thirty‐six cats received megavoltage radiation for sinonasal neoplasia. Carcinomas (n = 17) and lymphomas (n = 16) were most common, followed by sarcomas (n = 3). A majority of immunophenotyped lymphomas were B‐cell (89%). Diagnostic CT images were available for review on 33 cats. The stage distribution was as follows: T1 (n = 3), T2 (n = 11), T3 (n = 5), T4 (n = 14). Lymphomas were more commonly T2 (n = 8) while a majority of carcinomas were T4 (n = 8). The median survival times have not yet been reached for any stage or disease subtype. The most common cause for euthanasia was local recurrence (15/19, 79%). Four cats that died of other causes lived between 1,124 and 2,322 days.Conclusions:  Feline sinonasal neoplasia is uncommon, with carcinomas and lymphomas being most frequently encountered. Megavoltage radiation therapy appears to offer improved quality and duration of life for most patients, despite advanced staged at diagnosis in a majority.
Association of p53 Gene Mutation with the Prognosis of Canine Lymphoid Tumors
Authors: Koshino A. , Setoguchi A. , Ohno K. , Tsujimoto H. 
Published: September 2010

Introduction:  Many dogs with lymphoid tumors develop resistance to chemotherapy. As a mechanism of drug resistance in canine lymphoma, ATP‐dependent drug efflux by P‐glycoprotein was reported, however, inhibition of apoptosis mediated by P53 inactivation has not been investigated. In this study, we investigated the relationship between p53 gene mutation and clinical drug resistance in canine lymphoid tumors.Methods:  Tumor specimens were obtained from 44 dogs with lymphoid tumors. Mutations of p53 gene at exon 4–8 of these tumor tissues were examined by PCR‐SSCP (single strand conformational polymorphism) analysis, followed by nucleotide sequencing of the abnormal bands. The cases were treated with UW‐Madison protocol, and its response was evaluated by the tumor size or the number of peripheral leukemic cells.Results:  Of the 44 dogs, 15 dogs (34%) had p53 mutation, whereas 29 dogs (66%) were devoid of p53 mutation, before or during the chemotherapeutic protocol. Rate of good response (CR and PR) to chemotherapy was significantly lower in the dogs with p53 mutation (20%) than those without p53 mutation (55%)(p = 0.022). Median overall survival duration after examination of p53 mutation was significantly shorter in dogs with p53 mutation (101days) than those without p53 mutation (223days)(p = 0.008).Conclusions:  Lymphoid tumors with p53 mutations were shown to have worse prognosis than those without p53 mutation.
COX‐2 Expression in Feline Oral Squamous Cell Carcinoma (FOSCC)– An Immunohistochemical Study and Analysis of Survival
Authors: Hayes A. , Scase T. , Miller J. , Murphy S , Sparkes A. , Adams V. 
Published: September 2010

Introduction:  Cyclooxygenase‐2 (COX‐2) catalyses the rate‐limiting step in the conversion of arachidonic acid to eicosanoids and has been found to be overexpressed in many human and some animal cancers. Overexpression of COX‐2 in head and neck SCC in humans is associated with shorter survival times. Non‐resectable, FOSCC is a devastating disease with no effective therapy. Overexpression of COX‐2 in FOSCC may support the anecdotal use of NSAID therapy. Identification of a prognostic marker in cats may permit more effective, targeted therapy.Methods:  Immunohistochemistry was performed on formalin‐fixed, paraffin‐embedded tissue from 59 FOSCC cases using an indirect staining technique and feline foetal kidney as positive control. Polyclonal antiserum specific to COX‐1 and COX‐2 were used after antigen retrieval with pH6 citrate buffer. Retrospective, observational data were collected by practitioner questionnaires. A Kaplan‐Meier survival plot was derived.Results:  55/59 questionnaires were returned (93% response rate). Median age at presentation was 10.9 years (range 7–15.5). Median survival time was 44 days (95% CL: 31, 79). Preliminary results show that COX‐1 staining was positive in all tumour tissues and in 86.7%(13/15 cases) of normal tissues. COX‐2 staining was positive in 67.3%(37/55) of tumour tissues and absent in normal tissue. Results of proportional hazards regression for survival and multiple logistic regression for COX expression including age, sex, breed, prior NSAID administration, other medication and COX expression as potential explanatory variables will be presented.Conclusions:  These results indicated that COX‐1 and COX‐2 expression is seen in FOSCC but may not be predictive for survival.
Xenogeneic Human Tyrosinase DNA Vaccination Induces Specific Immune Response in Dogs with Advanced Malignant Melanoma
Authors: Liao J. , Gregor P. , Orlandi F. , Craft D. M. , Leung C. , Houghton A. N. , Wolchok J. D. , Bergman P. J. 
Published: September 2010

Introduction:  Xenogeneic melanosomal differentiation antigens, delivered in the form of a plasmid DNA vaccine, can overcome host immune ignorance/tolerance in preclinical animals to melanoma by: 1) generating humoral and cytotoxic T cell responses and 2) inducing protection from tumor challenge. Initial trials of human tyrosinase (huTyr) DNA vaccination of dogs with advanced malignant melanoma (Bergman et al, 2003) demonstrated safety and prolongation of survival with this therapeutic modality. We investigated antigen‐specific immunity in dogs receiving huTyr DNA vaccination.Methods:  Three cohorts of three dogs each with advanced (WHO stage II‐IV) canine malignant melanoma (CMM) received four biweekly IM injections (dose levels 100, 500, or 1,500 ug, respectively/vaccination) of huTyr plasmid DNA via the Biojector2000 jet delivery device. Sera samples were taken before and after vaccination to detect specific antibody formation to huTyr by Enzyme‐Linked ImmunoSorbent Assays (ELISAs) and flow‐cytometry.Results:  Three dogs have measurable, 2 to 4 fold huTyr‐specific antibody titers. Preliminary studies by flow‐cytometry have confirmed antibody response to huTyr by positive binding to endogenous human tyrosinase in SK‐Mel188 cells using post‐vaccinate serum.Conclusions:  Xenogeneic (huTyr) DNA vaccination generates antigen‐specific humoral responses, which may partially explain the previously reported clinical efficacy and anti‐tumor responses. Ongoing studies include: 1) a comprehensive analysis by flow‐cytometry to detect huTyr‐specific antibodies and 2) a quantitative measure of potential cytotoxic T‐cell responses in these dogs by the DNA vaccination.
A Candidate Second‐Generation Photosensitizer for Photodynamic Therapy in Veterinary Medicine
Authors: Borgatti‐Jeffreys A. , Hooser S. B. , Miller M. A. , Thomas R. M. , DeGortari A. , Lucroy M. D. 
Published: September 2010

Introduction:  Photodynamic therapy (PDT) involves the light activation of a drug within a tumor causing selective tumor cell death. Unfortunately, some photosensitizing drugs have been associated with adverse reactions in veterinary patients. Zinc phthalocyanine tetrasulfonate (ZnPcS4) is a promising second‐generation photosensitizer for use in veterinary medicine, however, it cannot be applied clinically until safety and efficacy data are available.Methods:  Increasing intraperitoneal doses of ZnPcS4 were given to Swiss Webster mice to assess acute toxicity. Based on mouse toxicity data, a phase I clinical trial of ZnPcS4‐based PDT in tumor‐bearing dogs was designed, using an accelerated titration scheme starting at 0.5% of the minimum toxic dose in mice. 24‐hours after ZnPcS4 administration tumors were irradiated with 675 nm light and dogs were evaluated by routine hematology and serum biochemistry at regular intervals after PDT.Results:  Doses >125 mg/kg were associated with acute toxicity and mortality in Swiss Webster mice, suggesting the minimum toxic dose is 120–125 mg/kg. One dog, a Golden retriever with a massive malignant fibrous histiocytoma, has been entered into the phase I clinical trial. No deleterious effects were noted after ZnPcS4 administration. Within 48 hours of PDT, the tumor was dark and necrotic, with no grossly visible changes to the surrounding normal tissues. Histological examination of the PDT‐treated tumor confirmed widespread necrosis and thrombosis consistent with PDT‐mediated damage. The owner reported no adverse effects after treatment.Conclusions:  Although preliminary data are encouraging, additional evaluation of ZnPcS4‐based PDT is required to determine its role in veterinary medicine.
The Biologic Behavior of Mast Cell Tumors in Pug Dogs
Authors: Prink A. L. , McNiel E. A. , O'Brien T. D. 
Published: September 2010

Introduction:  The purpose of this study was to quantitate the risk and to describe the behavior of mast cell tumors (MCT) in Pugs.Methods and Materials:  Using the Veterinary Medicine Database, the frequency of MCT in Pugs was compared to the frequency in other dogs using a Chi‐square test. To describe the biologic behavior of MCT in pugs, cases with histologically confirmed diagnosis were identified through the University of Minnesota (UMN) Diagnostic Laboratory and Veterinary Medical Center. Histology was reviewed by a single pathologist. Survival analysis was performed to determine the impact of clinical and histologic data on survival.Results:  The frequency of MCT diagnosis in Pugs was significantly increased compared to other dogs (OR = 2.28, 95% CI = 1.81–2.86). Twenty‐five purebred Pugs with a diagnosis of MCT were identified through UMN. Multiple cutaneous tumors were documented in 14 (56%) of the dogs. Most tumors were low to intermediate grade. Only three dogs have died of their disease. Sixteen are still living (median follow‐up = 660 days). The only factors predicting survival were grade, mitotic index and tumor size.Discussion:  Our data confirms MCT predisposition in Pugs and suggests that mast cell tumors in Pugs are relatively benign, despite the presence of multiple cutaneous tumors in most cases. Multiple tumors in breeds with predisposition to MCT may indicate separate primaries rather than advanced stage disease.This work was supported in part by NCI grants R03‐CA101030 and K08‐CA89530.
131‐I therapy for Advanced, Unresectable Thyroid Tumors in Dogs
Authors: Turrel J. , Burke B. , Ullman S. , McEntee M. , Page R. 
Published: September 2010

Introduction:  Greater than 50% of dogs with thyroid tumors present with surgically unresectable disease for which external beam radiotherapy has been reported to prolong survival. The success of 131I for control of thyroid tumors in cats and in humans suggests such therapy may also play a role in the management of canine thyroid cancer.Methods:  Thirty‐nine dogs with WHO stage II/III (invasive or ectopic; n = 32) or IV (metastatic; n = 7) thyroid tumors were treated with 131I alone. Changes in thyroid function, 99MTc‐pertechnetate (99MTc) scintigraphic changes, and tumor response were recorded. Dogs with ventral cervical tumors were evaluated for feasibility of surgical resection following 131I.Results:  Median overall survival was 839 days and 366 days for dogs with stage II/III and stage IV tumors, respectively. Thyroid hormone status, site and surgical resection were not associated with outcome in dogs with stage II/III tumors. Three dogs developed severe bone marrow suppression.Conclusions:  These findings suggest 131I should be investigated more thoroughly in dogs with thyroid tumors not considered surgical candidates to more clearly characterize the indications for therapy and followup recommendations. 131I dosimetry in dogs with thyroid tumors remains problematic. Administration of 131I is currently based on empiric recommendations and, in general, the treatment is well tolerated although additional studies are indicated to optimize response and minimize toxicity.
Identification of a Splice Variant of gp100 Expressed in Canine Melanoma Tumours
Authors: Stell A. , Dobson J. , Catchpole B. 
Published: September 2010

Introduction:  The melanoma‐associated antigen (MAA) gp100 is a glycoprotein expressed by melanocytes and is considered to be an important target for anti‐tumour immunity in human melanoma. The aim of the current study was to characterise the canine gp100 gene with a view to its inclusion in a DNA vaccine for treatment of canine oral malignant melanoma.Methods:  RNA was extracted from eight canine oral melanomas and seven control samples (pigmented oral mucocutaneous tissue) and cDNA synthesised. PCR was performed using human gp100 primers designed to generate a 421base pair (bp) fragment. In addition to the expected pcr product, a smaller amplicon (∼260 bp) was present in all tumours and control tissues. Both PCR amplicons were cloned and sequenced. The gp100 genomic DNA sequence was identified from the dog genome resource (NCBI).Results:  The 421 bp fragment of canine gp100 shared 90.8% identity with human gp100. This partial sequence was located on dog chromosome 10 (CFA10_contig 2982). Further analysis, using the human gp100 gene as a reference, allowed the complete canine gp100 coding sequence to be identified from the dog genome. Sequence analysis of the small PCR product showed it to be a splice variant of gp100 with exon 5 deleted.Conclusion:  The canine gp100 sequence has been identified and this will allow DNA vaccine constructs containing this MAA to be developed. The splice variant of gp100 with exon 5 deleted was not tumour‐specific and was expressed in both melanomas and normal pigmented tissue.
RT‐PCR based Tyrosine Kinase Display Profiling of Canine Melanoma: IGF‐1 Receptor as a Potential Therapeutic Target
Authors: Huelsmeyer M. K. , Mitzey A. , Baker T. , Swaab M. , Thamm D. H. 
Published: September 2010

Introduction:  There is a wealth of information available regarding tyrosine kinase (TK) expression in human cancer, however there is minimal information regarding the expression and function of TKs in canine melanoma, and no attempt has been made to systematically define the repertoire of TKs expressed. This study employed a molecular technique called RT‐PCR display to simultaneously evaluate the expression of up to 30 different TKs in a canine melanoma cell line.Materials and Methods:  mRNA was extracted and reverse‐transcribed from the 17CM98 canine melanoma line, then subjected to PCR using degenerate primers coding for highly conserved regions which flank the kinase domains of many receptor and nonreceptor TKs. The resulting product was ligated into a plasmid vector and used to transform E. coli. Multiple colonies were isolated, and the cDNA inserts sequenced.Results and Conclusions:  Sequencing 46 clones yielded canine homologs of IGF‐1R (50%), JAK1 (17%), PDGFR‐α(11%), FGFR1 (9%), Axl (7%), c‐Abl (4%), and PTK2 (2%). Interestingly, IGF‐1R, JAK1 and Axl were detected using a similar technique in human melanoma, supporting the cross‐species validity of this assay. Given the abundance of IGF‐1R clones, we sought to determine the biologic effect of rhIGF‐1 in 17CM98 cells. IGF‐1 stimulated IGF‐1R phosphorylation, cell proliferation and VEGF production in 17CM98, and protected the cells from serum starvation‐induced apoptosis. Expression of IGF‐1R mRNA was detected in 5 of 5 additional canine melanoma cell lines evaluated, suggesting that IGF‐1R expression may be common in canine melanoma cells and providing a novel target for future therapy.
Evaluation of Liposomal Radiochemotherapy for Treatment of Cancer
Authors: Jonasdottir T. J. , Borrebæk J. , Bruland ØS , Salberg G. , Moe L. , Larsen R. H. 
Published: September 2010

Introduction:  Pegylated liposomes target solid tumors by exploiting the capillary leakage properties of tumor neovasculature. The goal of the study was to investigate distribution and tumor targeting properties of the alpha‐particle emitter 223Ra, encapsulated in doxorubicin‐containing‐liposomes (Caelyx®/Doxil®).Methods:  Caelyx® was given before the injection of liposomal 223Ra to reduce the reticulo‐endothelial‐system uptake. A pilot study was conducted to determine the optimal time interval between the pre‐treatment/treatment. Subsequently a more extensive distribution study was performed in normal BalbC mice. In addition, distribution and tumor uptake was evaluated in a human osteosarcoma xenograft mice model and in a dog with spontaneous osteosarcoma.Results:  Optimal blood‐to‐liver and blood‐to‐spleen ratios of liposomal radium was achieved in animals that received pre‐treatment with Caelyx® 4 days in advance. Blood clearance was relatively slow, in mice t1/2 was ∼28 h (BalbC mice) and in the dog t1/2 was ∼ 39 h. In mice the liver uptake appeared to be relatively low in contrast to the spleen, where there was a significant uptake. In the dog the uptake in both liver and spleen was moderate. In the xenograft model there was generally a higher retention of activity in the tumor vs. soft tissue. In the dog the 24 h uptake was considerably higher in both calcified and non‐calcified tumor metastases of different organs, than in normal tissue.Conclusions:  Liposomal 223Ra has a relevant biodistribution and blood clearance for tumor targeting. More extensive future studies are supported by the favourable tumor/normal‐tissue ratio in a dog with spontaneous osteosarcoma.
REVIEWS OF EXHIBITIONS
Authors: Hankins James 
Published: September 2010

Virgilio e il Chiostro. Manoscritti di autori classici e civiltà monastica, Abbazia di Montecassino, 8 July 1996–8 December 1996; Virgilio e il Chiostro. Manoscritti di autori classici e civiltà monastica, edited by Mariano Dell'Omo, Rose, Rome, 1996Vedere i Classici. L'illustrazione libraria dei testi antichi dall'età romana a1 tardo medioevo', Musei Vaticani, Salone Sistino, 9 October 1996–19 April 1997. Vedere i Classici. L'illustrarione libraria dei testi antichi dall'età romanu a1 tardo medioevo, edited by Marco Buonocore, Rose, Rome, 1996Umanesimo e Padri della Chiesa. Manoscritti e incunaboli di testi patristici da Francesco Petrarca a1 primo Cinquecento, Biblioteca Medicea Laurenziana, 5 February 1997–9 August 1997. Umanesimo e Padri della Chiesa. Manoscritti e incunuboli di testi patristici da Francesco Petrarca a1 primo Cinquecento, edited by Sebastiano Gentile, Rose, Rome, 1997
Who Pays More for Food?
Authors: Stewart Hayden , Blisard Noel 
Published: September 2010

AbstractBuilding on research with unit values, we demonstrate how a household's per serving and total vegetable expenditures depend on both the characteristics of the household and on its location. The lower a household's income, for example, the lower is vegetable spending, all else constant. However, households living in communities with high real estate prices, or with a high incidence of poverty, among other things, tend to pay more. Simulations further illustrate the effect that a community's characteristics can have on a household's vegetable spending, if the household lives in each of 10 cities in the United States.
Assessing the Impact of the ‘Decoupling’ Reform of the Common Agricultural Policy on Irish Farmers’ Off‐farm Labour Market Participation Decisions
Authors: Hennessy Thia C. , Rehman Tahir 
Published: September 2010

AbstractThis paper assesses the impact of the ‘decoupling’ reform of the Common Agricultural Policy on the labour allocation decisions of Irish farmers. The agricultural household decision‐making model provides the conceptual and theoretical framework to examine the interaction between government subsidies and farmers’ time allocation decisions. The relationship postulated is that ‘decoupling’ of agricultural support from production would probably result in a decline in the return to farm labour but it would also lead to an increase in household wealth. The effect of these factors on how farmers allocate their time is tested empirically using labour participation and labour supply models. The models developed are sufficiently general for application elsewhere. The main findings for the Irish situation are that the decoupling of direct payments is likely to increase the probability of farmers participating in the off‐farm employment market and that the amount of time allocated to off‐farm work will increase.
Technology Adoption and Pest Control Strategies Among UK Cereal Farmers: Evidence from Parametric and Nonparametric Count Data Models
Authors: Sharma Abhijit , Bailey Alastair , Fraser Iain 
Published: September 2010

Abstract This paper examines the intensity of technology adoption and integrated pest management strategies employed by UK farmers, using both parametric and nonparametric methods. We employ a unique survey dataset collected from UK cereal farmers to assess the determinants of technology adoption in relation to pest management. Our preferred model specification is nonparametric, with models estimated yielding broadly similar results, with some important qualitative differences. All models indicate that total area farmed is positively related to the number of technologies adopted, whereas the number of years of experience of the farmer is negatively related. We also find evidence with our nonparametric specification of significant statistical differences for number of adoptions by region across the UK.